| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/27/2001 | CA2401870A1 Cyclic .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-.alpha. |
| 09/27/2001 | CA2401749A1 Compounds and methods to treat alzheimer's disease |
| 09/27/2001 | CA2401728A1 Difluorobutyric acid metalloprotease inhibitors |
| 09/27/2001 | CA2401368A1 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| 09/27/2001 | CA2400645A1 Taxane anticancer agents |
| 09/27/2001 | CA2400637A1 Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma |
| 09/27/2001 | CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | CA2400118A1 Oxazolidinone tablet formulation |
| 09/27/2001 | CA2400114A1 Container for linezolid intravenous solution |
| 09/27/2001 | CA2400000A1 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents |
| 09/27/2001 | CA2399991A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
| 09/27/2001 | CA2399985A1 Compounds with 5-ht activity useful for controlling visual field loss |
| 09/27/2001 | CA2389173A1 Agent for treating hepatitis c |
| 09/27/2001 | CA2383848A1 Diagnosis of a person's risk of developing alcoholism |
| 09/27/2001 | CA2374073A1 Novel polypeptides and nucleic acids encoding same |
| 09/27/2001 | CA2364268A1 Di-substituted iminoheterocyclic compounds |
| 09/26/2001 | EP1136571A2 Detection of polymorphisms in the MxA gene to predict the response of an hepatitis C virus infected individual to interferon therapy |
| 09/26/2001 | EP1136561A2 Targeting gene therapy |
| 09/26/2001 | EP1136547A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/26/2001 | EP1136490A1 New forms of paroxetin hydrochloride |
| 09/26/2001 | EP1136487A1 Nicotine salts with improved taste, process for their preparation and use thereof as smoking cessation agents |
| 09/26/2001 | EP1136482A1 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| 09/26/2001 | EP1136479A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease |
| 09/26/2001 | EP1136475A1 Piperidine and piperazine compounds for use in the treatment of Alzheimer |
| 09/26/2001 | EP1136474A1 1-Acetyl-5-bromo-4,6-dimethyl-indoline |
| 09/26/2001 | EP1136081A1 Sustained-release compositions for the parenteral administration of macrolides |
| 09/26/2001 | EP1136079A1 Agents for retarding change of hormone-dependent cancer into hormone-independent cancer |
| 09/26/2001 | EP1136078A2 Combination of angiotensin converting enzyme inhibitor and side- effect-reduced amount of aldosterone antagonist |
| 09/26/2001 | EP1136075A1 Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| 09/26/2001 | EP1136073A1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 09/26/2001 | EP1136072A1 Preparations for intraurethral administration |
| 09/26/2001 | EP1136071A2 Use of glycogen phosphorylase inhibitors |
| 09/26/2001 | EP1136067A1 Oral formulations of medicaments |
| 09/26/2001 | EP1136065A1 Formulations and methods for reducing skin irritation |
| 09/26/2001 | EP1136062A1 Cosmetic compositions comprising sesquiterpene alcohol |
| 09/26/2001 | EP1135998A1 Use of synthetic triglycerides based on conjugated linoleic acid as antioxydant in foodstuffs |
| 09/26/2001 | EP1135996A1 Use of synthetic triglycerides based on conjugated linoleic acid as colour stabilisor in foodstuffs |
| 09/26/2001 | EP1135995A2 Composition and method for stabilising proanthocyanidin |
| 09/26/2001 | EP1135991A2 Oil composition and use thereof |
| 09/26/2001 | EP1135688A2 Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3) |
| 09/26/2001 | EP1135513A1 Adenovirus-mediated gene therapy |
| 09/26/2001 | EP1135509A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/26/2001 | EP1135504A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 09/26/2001 | EP1135503A2 DRUG TARGETS IN $i(CANDIDA ALBICANS) |
| 09/26/2001 | EP1135501A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/26/2001 | EP1135496A2 Ucp5 |
| 09/26/2001 | EP1135485A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 09/26/2001 | EP1135482A1 Cancer cell vaccine |
| 09/26/2001 | EP1135481A1 New oligomeric conjugates liable to transfer biological molecules into cells |
| 09/26/2001 | EP1135470A2 Recombinant methods and materials for producing epothilone and epothilone derivatives |
| 09/26/2001 | EP1135417A1 Polysaccharide chiral esters, one of the methods for preparing them and their uses for obtaining optically enriched acids or chiral chromatography |
| 09/26/2001 | EP1135412A2 Tumor necrosis factor receptor homologue-1 (trh1) |
| 09/26/2001 | EP1135403A1 17beta-acyl-17alpha-propynyl-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 09/26/2001 | EP1135401A1 Glyceryl nucleotides, method for the production thereof and their use |
| 09/26/2001 | EP1135400A1 Hygromycin a derivatives as antibacterial agents |
| 09/26/2001 | EP1135395A1 Crystalline salts of a carbapenem antibiotic |
| 09/26/2001 | EP1135393A2 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers |
| 09/26/2001 | EP1135391A1 Novel triazolo(4,5-d)pyrimidine compounds |
| 09/26/2001 | EP1135390A1 Methotrexate derivatives |
| 09/26/2001 | EP1135389A1 1,4-diazabicyclo 3.2.2]nonane derivatives, their preparation and therapeutic application |
| 09/26/2001 | EP1135384A1 Process for the production of paroxetine hydrochloride propan-2-ol solvate |
| 09/26/2001 | EP1135383A1 Mixed paroxetine propan-2-ol solvates |
| 09/26/2001 | EP1135382A1 Method of producing paroxetine hydrochloride |
| 09/26/2001 | EP1135381A1 Eletriptan hydrobromide monohydrate |
| 09/26/2001 | EP1135379A1 Antitumor dibenzofluorene derivatives |
| 09/26/2001 | EP1135378A1 Benzamide derivatives and their use as apob-100 secretion inhibitors |
| 09/26/2001 | EP1135377A1 Novel compounds |
| 09/26/2001 | EP1135374A1 Benzimidazole compounds that are vitronectin receptor antagonists |
| 09/26/2001 | EP1135373A1 Crystalline form of an octahydro-benzo(f)quinolin-3-one derivative |
| 09/26/2001 | EP1135371A1 Beta-alanine derivatives as alpha 4 integrin inhibitors |
| 09/26/2001 | EP1135370A2 Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds |
| 09/26/2001 | EP1135367A1 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same |
| 09/26/2001 | EP1135365A1 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction |
| 09/26/2001 | EP1135361A1 Therapeutic product and its use |
| 09/26/2001 | EP1135360A1 Novel 3-alkoxybenzylamine derivatives and their use as medicines for treating schizophrenia |
| 09/26/2001 | EP1135359A1 Derivatives of (-)-venlafaxine and methods of preparing and using the same |
| 09/26/2001 | EP1135358A1 Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| 09/26/2001 | EP1135193A1 Agents provided for treating tumors, based on liposomes, and containing tamoxifen |
| 09/26/2001 | EP1135178A1 Polymeric coatings with controlled delivery active agents |
| 09/26/2001 | EP1135168A1 Peptides carrying substances across the blood brain barrier |
| 09/26/2001 | EP1135167A2 Methods and formulations for reducing circulating antibodies |
| 09/26/2001 | EP1135166A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/26/2001 | EP1135164A1 Method for the treatment of inflammation |
| 09/26/2001 | EP1135163A1 Topical compositions comprising ascomycins |
| 09/26/2001 | EP1135161A1 Chemotherapeutic composition and method |
| 09/26/2001 | EP1135160A2 Boron neutron capture therapy using pre-targeting methods |
| 09/26/2001 | EP1135157A1 Method for regulating the permeability of the blood brain barrier |
| 09/26/2001 | EP1135150A1 Self-emulsifying compositions for drugs poorly soluble in water |
| 09/26/2001 | EP1135146A1 Pharmaceutical composition containing fish oil, vitamin e and c and acetylsalicyl acid against arteriosclerosis |
| 09/26/2001 | EP1135144A1 Compositions and methods for regulating bacterial pathogenesis |
| 09/26/2001 | EP1135143A1 Immunomodulatory methods using carbohydrate antigens |
| 09/26/2001 | EP1135140A1 Use of ibandronate for promoting osseointegration of endoprostheses |
| 09/26/2001 | EP1135139A1 Micronized eplerenone compositions |
| 09/26/2001 | EP1135138A2 Use of 17-ketosteroids for the treatment of malaria and trypanosomiasis |
| 09/26/2001 | EP1135137A1 Copolymer compositions for treating viral infections |
| 09/26/2001 | EP1135136A1 Pharmaceutical compositions containing olanzapine-n-oxide |
| 09/26/2001 | EP1135135A1 Chk1 kinase inhibitors |
| 09/26/2001 | EP1135134A1 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
| 09/26/2001 | EP1135132A2 Inhibitors of multidrug transporters |
| 09/26/2001 | EP1135131A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |